Literature DB >> 29193364

The influence and mechanism of ligustilide, senkyunolide I, and senkyunolide A on echinacoside transport through MDCK-MDR1 cells as blood-brain barrier in vitro model.

Qin Zheng1, Yu Tang1, Peng-Yi Hu1, Dan Liu1, Delin Zhang2, Pengfei Yue1, Yuanyuan Guo1, Ming Yang1.   

Abstract

Efficient transcytosis across the blood-brain-barrier is an important strategy for accessing drug targets within the central nervous system. Ligusticum chuanxiong Hort. was used as a messenger drug to increase the distribution of drugs in brain tissue in Traditional Chinese Medicine. The present study investigates the transport of echinacoside (ECH) through MDCK-MDR1 cell and the effects of ligustilide (LIG), senkyunolide A (SENA) and senkyunolide I (SENI) in chuanxiong on its transport. The results indicated that the absorption of ECH was relatively poor in MDCK-MDR1cells, and was concentration dependent and not saturable. The P-glycoprotein inhibitor verapamil could significantly increase the transport of ECH. It indicated that the transport mechanism might be passive diffusion as the dominating process with the active transportation mediated mechanism involved. The increased apparent permeability of ECH in A → B direction by ethylenediaminetetraacetic acid-Na2 suggested that ECH was absorbed via the paracellular route. The transport of ECH in A → B direction significantly increased when co-administrated with increasing concentrations of LIG, SENI and SENA. Western blot analysis and a decrease in transepithelial electrical resistance during the permeation experiment indicated that LIG, SENI and SENA had enhanced the transport of ECH in the BBB models attribute to down-regulate the expressions of claudin-5 and zonula occludens-1 expression.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Echinacoside; Ligusticum chuanxiong Hort; ZO-1; blood-brain barrier; claudin-5; volatile oil

Mesh:

Substances:

Year:  2017        PMID: 29193364     DOI: 10.1002/ptr.5985

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  6 in total

1.  Coexisting flavonoids and administration route effect on pharmacokinetics of Puerarin in MCAO rats.

Authors:  Pengyue Li; Linying Zhong; Linjie Yang; Jie Bai; Yang Lu; Shouying Du
Journal:  Open Life Sci       Date:  2020-07-03       Impact factor: 0.938

2.  The Combination of Aquilaria sinensis (Lour.) Gilg and Aucklandia costus Falc. Volatile Oils Exerts Antidepressant Effects in a CUMS-Induced Rat Model by Regulating the HPA Axis and Levels of Neurotransmitters.

Authors:  Huiting Li; Yuanhui Li; Xiaofei Zhang; Guilin Ren; Liangfeng Wang; Jianzhe Li; Mengxue Wang; Tao Ren; Yi Zhao; Ming Yang; Xiaoying Huang
Journal:  Front Pharmacol       Date:  2021-02-24       Impact factor: 5.810

3.  Identification of Chemical Components of Qi-Fu-Yin and Its Prototype Components and Metabolites in Rat Plasma and Cerebrospinal Fluid via UPLC-Q-TOF-MS.

Authors:  Hengyu Li; Hongwei Zhao; Yong Yang; Dongmei Qi; Xiaorui Cheng; Jiafeng Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-28       Impact factor: 2.629

Review 4.  Research Advances in Cardio-Cerebrovascular Diseases of Ligusticum chuanxiong Hort.

Authors:  Dan Li; Yu Long; Shuang Yu; Ai Shi; Jinyan Wan; Jing Wen; Xiaoqiu Li; Songyu Liu; Yulu Zhang; Nan Li; Chuan Zheng; Ming Yang; Lin Shen
Journal:  Front Pharmacol       Date:  2022-01-31       Impact factor: 5.810

5.  Senkyunolide A inhibits the progression of osteoarthritis by inhibiting the NLRP3 signalling pathway.

Authors:  Minglei Shao; Dongwei Lv; Kai Zhou; Haijun Sun; Zhitao Wang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

6.  Ligustilide improves aging-induced memory deficit by regulating mitochondrial related inflammation in SAMP8 mice.

Authors:  Wen-Li Zhu; Jia-Yi Zheng; Wei-Wu Cai; Zhao Dai; Ben-Yue Li; Ting-Ting Xu; Hao-Fei Liu; Xiao-Qi Liu; Su-Fen Wei; Yi Luo; Hong Wang; Hua-Feng Pan; Qi Wang; Shi-Jie Zhang
Journal:  Aging (Albany NY)       Date:  2020-02-16       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.